Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -202620252024202320222021202020192018201720162015 4 February 2022 Disclosure of a transparency notification Regulated information 25 January 2022 Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes Non-regulated information 10 January 2022 BIOCARTIS MEETS 2021 KEY OBJECTIVES Regulated information 9 December 2021 Biocartis’ Idylla™ SARS-CoV-2 testing Successfully Detects Omicron Variant Non-regulated information 30 November 2021 SeptiCyte® RAPID Receives 510(k) clearance by US FDA Non-regulated information 16 November 2021 New Study Demonstrates Idylla™ EGFR Mutation Test (CE-IVD) Shortens Time to Patient Management Decisions for Patients with Non-Small Cell Lung Cancer Non-regulated information 10 November 2021 BIOCARTIS Q3 2021 BUSINESS UPDATE Regulated information 12 October 2021 Disclosure of a transparency notification Regulated information 23 September 2021 Biocartis Announces Restart of its High-Throughput Cartridge Manufacturing Line Non-regulated information 13 September 2021 Disclosure of a transparency notification Regulated information Pagination First page « First Previous page ‹‹ … Page 6 Page 7 Page 8 Page 9 Current page 10 Page 11 Page 12 Page 13 Page 14 … Next page ›› Last page Last »